100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.


Read more
  • 0

Pharma layoffs in 2023: Companies making cuts

[Image courtesy of Adobe Stock]

A recession in 2023 is highly probable. Some two-thirds of economists surveyed at the World Economic Forum in Davos said they anticipated an economic downturn this year. 

Given the difficult economic situation, a growing number of pharmaceutical firms are reducing staff. Several companies announced cuts at the end of 2022, including Catalent and Novartis. 

The following is a list of some significant pharma layoffs announced at the outset of 2023.

Amgen cuts 300 workers 

The company is undergoing a restructuring effort that includes layoffs of around 300 employees. The pharma layoffs will primarily affect employees in the commercial team based in the U.S., according to a report obtained from Endpoints. 

Merck KGaA lays off 133

Merck KGaA, Darmstadt, Germany, is letting go of 133 jobs in Billerica, Massachusetts, as part of a restructuring effort, according t…

Read more
  • 0